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18 (2004) 919–937Management of acute bronchitis
in healthy adults
Eva Aagaard, MD, Ralph Gonzales, MD, MSPH*
Department of Medicine, University of California, San Francisco, 3333 California Street,
Box 1211, San Francisco, CA 94118, USA
Acute respiratory infections (ARIs) are the most common infections in
humans. ARIs (nonspecific upper respiratory infections, otitis media,
sinusitis, pharyngitis, bronchitis, and pneumonia) account for half of acute
conditions each year [1], and consistently rank among the top 10 reasons for
ambulatory visits in the United States [2–12]. Acute bronchitis episodes
represent a significant portion of these illnesses. Data from the National
Health Interview Survey suggest that 4% to 5% of all adults experience one
or more episodes of acute bronchitis each year [1]. Furthermore, over 90%
of acute bronchitis episodes will come to medical attention [1].
Acute bronchitis is a clinical diagnosis applied to otherwise healthy adults
with acute respiratory illness of 1 to 3 weeks’ duration. Acute bronchitis
usually is distinguished from other ARIs by the predominance of cough,
often accompanied by other respiratory and constitutional symptoms, and
the absence of findings suggestive of pneumonia. The importance placed on
sputum production and wheezing when making the diagnosis of acute
bronchitis varies by physician [13–16]. Cough lasting longer than 3 weeks
should be considered ‘‘persistent’’ or ‘‘chronic’’ cough [17,18], and is not
discussed here because the diagnostic considerations are significantly
different than those of acute bronchitis.
This article focuses on acute bronchitis in otherwise healthy individuals,
not on patients who have underlying heart or lung disease or immunosup-
pression, who generally have been excluded from trials evaluating etiology
of and treatment for acute bronchitis. The extent to which one can
generalize from the data presented herein is unknown.
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Clinical features of uncomplicated acute bronchitis develop in sequential
phases. Acutely, there is direct inoculation of the tracheobronchial epi-
thelium, characterized clinically by variable constitutional symptoms, in-
cluding fever, malaise, and myalgias. These symptoms usually last 1 to 5
days, depending on the infectious agent. This phase of illness is often
indistinguishable from other acute upper respiratory tract infections. Most
uncomplicated upper respiratory infections improve substantially within 5
to 7 days [19,20]. In patients for whom the diagnosis of acute bronchitis
would be appropriate, however, the acute phase is followed by a second,
protracted phase characterized by persistent cough, often accompanied by
phlegm production or wheezing. This second phase usually lasts 1 to 3
weeks, and has as its underlying pathophysiology the hypersensitivity of the
tracheobronchial epithelium and airway receptors (reactive airway disease).
During the protracted phase, pulmonary function tests (PFTs) are fre-
quently abnormal and do not seem to be related to either the acute cytopathic
effects of the infection or the type of infection (bacterial or viral) [21–25].
Vagal-mediated airway hyperresponsiveness has been shown to coincide with
repair of the bronchial epithelium [26]. Other mechanisms of bronchial
hyperresponsiveness, such as adrenergic-cholinergic tone imbalance and IgE-
mediated histamine release, also may be present. PFT abnormalities seem to
be common in acute bronchitis, with approximately 40% of patients dem-
onstrating significant abnormalities by forced expiratory volume (FEV1) or
histamine challenge [27,28]. PFT abnormalities are usually transient, typically
resolving after 2 to 3 weeks, although they may last as long as 2 months [27–
29]. Recurrent episodes of ‘‘acute bronchitis’’ may suggest underlying asthma
[30,31]. Although undiagnosed asthma should be considered in patients who
have acute cough illness, this diagnosis is difficult to establish because
bronchial hyperresponsiveness and PFT abnormalities are frequent in
patients who have acute bronchitis. Suspicion and work-up for asthma
should be reserved for patients with cough lasting longer than 3 weeks [17].
Microbiology of acute bronchitis
Most acute bronchitis cases seem to have a nonbacterial etiology [29,32,33].
Microbiologic study of acute bronchitis, however, similar to community-
acquired pneumonia, can identify a pathogen in only 16% to 55% of cases
[32,34]. The significant variability in the frequency of isolation of any pathogen
and the types of pathogens identified reflects the patients studied, available
technology to identify certain viral and atypical pathogens, and the epidemic
nature of the agents that cause acute bronchitis. Additionally, noninfectious
causes of acute bronchitis also likely represent some of these cases. Occult
asthma, allergic, and occupational exposures should be considered, although
their prevalence in adults with acute cough illness remains unclear.
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Respiratory viruses seem to cause or serve as a copathogen in most cases of
acute bronchitis in epidemiologic studies. The specific viruses most frequently
associated with acute bronchitis, in order of frequency of occurrence, are
influenza, parainfluenza, respiratory syncitial virus (RSV), coronavirus,
adenovirus, and rhinoviruses.
Recent studies have demonstrated the importance of RSV as the etiology
of ARIs in adults [35,36]. The impact of RSV is greatest in the elderly,
particularly those living in long-term care facilities, and those with underlying
heart and lung disease andmalignancy [37]. Infection among exposed adults is
common, with attack rates approaching 50%, particularly in households with
children infected with RSV and in institutional settings [24,37]. Most young
andmiddle-aged adults develop asymptomatic ormildly symptomatic disease,
often closely resembling influenza [38]. RSV can be associated with more
severe clinical disease and significant morbidity, even in otherwise healthy
adults [24]. This morbidity seems to be in part secondary to induced airway
hyperreactivity.
In the elderly and institutionalized, lower respiratory illness with RSV is
common, with most studies reporting rates of pneumonia and death from
10% to 20% and 2% to 5%, respectively [37]. One report of an outbreak on
a geriatrics ward found intense coughing and fever in 96% of patients,
productive cough in 64%, and evidence of bronchopneumonia in 40% [39].
In this study, it is unclear whether RSV or secondary bacterial infection
caused these pneumonias.
Human metapneumovirus (hMPV), a paramyxovirus [33,40], has
emerged recently as an important cause of lower respiratory tract illness
and acute bronchitis. Human MPV has been detected in children, adults, the
elderly, and the immunocompromised in the Netherlands, Australia, North
America, the United Kingdom, and Finland [41–45]. In one study, hMPV
was second only to RSV as a cause of respiratory tract illness presenting to
a university hospital in the Netherlands [45].
Similar to RSV, hMPV is primarily an illness of the winter months, most
commonly causing significant illness in young children and immunocom-
promised and elderly individuals. Studies suggest that 25% to 50% of
hMPV-positive patients who have significant respiratory tract illness have
underlying disease [46,47]. Among otherwise healthy adults, hMPV likely
causes predominantly mild respiratory illness, but may cause a small but
significant portion (approximately 3%) of acute respiratory illness requiring
medical attention [46–48].
Bacterial bronchitis
When microbiologic studies are performed on select patients who have
uncomplicated acute bronchitis in nonoutbreak settings, less than 10% of
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Chlamydia pneumoniae, and Mycoplasma pneumoniae are the only bacterial
pathogens that have been established as causes of acute bronchitis. Although
studies have reported the presence of Streptococcus pneumoniae,Haemophilus
influenzae, and Moraxella catarrhalis in adults with acute bronchitis, these
studies generally failed to exclude patients who had underlying lung disease,
failed to distinguish between colonization and infection [49], or did not
differentiate adequately patients who had pneumonia from those who had
acute bronchitis when determining causative agents [33]. Furthermore, acute
viral respiratory infections seem to increase the proliferation of these bacteria
among the oropharyngeal flora [50], further complicating the issue of
colonization versus infection. Therefore, sputum Gram stain and culture for
common bacterial pathogens have no clinical usefulness in patients who have
acute bronchitis.
Mycoplasma pneumoniae and C pneumoniae have been recognized as
possible causes of acute bronchitis since the 1980s [51,52]. Attack rates vary
highly, reflecting the seasonal, geographic, and epidemic nature of these
infections [21,27,33,53–60]. Studies attempting to distinguish these atypical
bacterial pathogens from viral etiologies have shown that patients infected
with atypical bacterial pathogens tend to present to medical attention much
later than those with confirmed viral bronchitis [21,60,61], and are more
likely to have wheezing on clinical examination [21]. In several studies,
although these pathogens were present by antibody titer or gene
amplification, treatment with antibiotics appropriate to atypical pathogens
did not change outcome [33,62–65]. This suggests that in acute bronchitis,
C pneumoniae and Mycoplasma pneumoniae may reflect copathogens or
inciting factors for secondary infectious processes, rather than the etiologic
agent. Alternatively, because patients with atypical bacterial pathogens
present late in the course of illness, the acute infectious process may have
resolved with only residual reactive airway disease present at the time of
presentation for medical care.
B pertussis causes acute bronchitis in previously immunized adults.
Natural infection and vaccination with whole-cell and acellular vaccines
induce protection from infection for a limited time [21,66–71]. Thus,
adolescents and adults gradually may become susceptible to infection again.
Symptomatic adult pertussis requiring medical attention occurs at a rate of
71 to 507 per 100,000 population per year (0.1%–0.5% of the population
per year) [72–76]. This pool of frequently undiagnosed pertussis [77]
provides a reservoir for potentially serious infections in young infants who
either are unvaccinated or whose vaccinations are not yet fully effective [78].
The gradual decrease in protection against pertussis likely explains part
of the wide variation in presenting symptoms in previously immunized
adults. Adults with pertussis generally present with persistent cough, with
a mean duration of 36 to 48 days [72,75,77,79–82]. When prolonged cough
(longer than 1 week) is present, a significant portion of patients will have
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75,79,83–88]. Cough is mostly paroxysmal, and often disturbs sleep.
Choking or vomiting and whooping can be present, but less commonly
than in children or previously unimmunized adults.
Some have suggested that booster pertussis immunizations for adults or
adolescents may curb illness in infants [89]. Whole-cell and acellular
pertussis vaccines are well tolerated, with primarily local side effects [90–
92]. Only one study has assessed the efficacy of acellular (aP) vaccines in
adults [93]. Because of the small sample size of the trial, few pertussis cases
were reported (n = 12), and no point estimate of efficacy could be given.
The incidence of primary pertussis cases was decreased in the aP group (0.8
per 1000 person-years; 95% CI 0.0–2.1), however, compared with the
control group (3.7 per 1000 person-years; 95% CI 1.2–6.2). An epi-
demiologic model has suggested that a high coverage of adults (greater than
85%) would be needed to reduce effectively the number of cases of infant
pertussis [94].
Antibiotic therapy does not seem to decrease duration of symptoms for
pertussis unless initiated within 7 to 10 days of the onset of illness [95–97].
Macrolide prophylaxis during outbreak situations and after intrafamilial
contacts seems effective [77,98], however, and decreases spread of disease
[96,97].
Distinguishing pneumonia from acute bronchitis
In the absence of significant comorbid conditions or asthma, the primary
objective when evaluating patients who have acute cough illness is excluding
pneumonia. The prevalence of pneumonia in patient populations presenting
with ARIs varies significantly across study populations, ranging from 3% to
10% in most studies [33,99–101]. Cohort studies have identified clinical
features useful for determining which patients do not have pneumonia
[99,101–104]. The absence of abnormal vital signs (heart rate greater than
100 beats/minute, respiratory rate greater than 24 breaths/minute, oral
temperature above 100.5F) and chest examination (focal consolidation; eg,
rales, egophony, fremitus) reduces the likelihood of pneumonia sufficiently
to render further diagnostic testing unnecessary [101]. The specificity (67%–
76%), but not sensitivity (62%–71%), of these clinical prediction rules for
radiographic pneumonia exceeded physician judgment in a well-designed
validation study of 290 adult patients who had acute cough illness [100].
Notably absent from these decision rules is the presence or absence of
purulent sputum because purulence (by itself) is a poor predictor of bacterial
infections [105,106].
Applying the pneumonia clinical prediction rules should help inform the
decision about ordering a chest radiograph, but cannot substitute for clinical
judgment. The pneumonia clinical prediction rules have limited application in
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monia (and without vital sign or examination abnormalities) [107].
Conversely, during the influenza season many patients will have fever or
tachycardia but not pneumonia. As a result, chest radiography often is
overused in the elderly and during influenza season. In settings where chest
radiography is not available readily (eg, many private office practices or rural
locations), patients who have cough illness (particularly elderly) may be
prescribed antibiotics to safeguard against missing a case of pneumonia.
Rapid blood tests for bacterial infections
C-reactive protein
A rapid, office-based diagnostic test that improves sensitivity and
specificity of detecting pneumonia could be a valuable addition to the
current evaluation strategies for patients who have acute cough illness [108].
European experience with an office-based, rapid c-reactive protein (CRP)
test, as well as a recent study conducted in the United States, suggests
considerable potential to improve diagnostic and treatment decisions for
adults with cough illness [109–117]. CRP synthesis is stimulated in response
to many inflammatory conditions, and levels increase preferentially (but not
exclusively) by bacterial (versus viral) infections. The serum levels of CRP
associated with bacterial infections are 10 to 50 fold higher than those used
to predict atherosclerotic heart disease.
Despite widespread use in Europe, and recent US Food and Drug
Administration approval of a rapid CRP test in the United States, the role
of rapid CRP testing in the management of adults with acute cough illness
has not been defined rigorously. Most studies found a high sensitivity (80%–
100%), but CRP levels may lack the specificity (60%–70%) necessary to
diagnose bacterial infections in isolation. Integrating CRP testing into
a clinical algorithm is one strategy to improve on its specificity while taking
advantage of its sensitivity for detecting acute bacterial infections such as
pneumonia. Future studies assessing the effectiveness of a CRP-based
clinical algorithm are necessary.
Procalcitonin
Recent studies of procalcitonin in serum also have shown levels to
distinguish bacterial from viral illnesses [118,119]. Early procalcitonin assays
had a limited functional assay sensitivity (0.3–0.5 lg/L), and therefore were
not accurate for the diagnosis of early or localized infections [120,121]. A
newer assay with improved functional sensitivity (0.06 lg/L) has become
available in Europe, however. One recent study adopting a test-based
clinical algorithm with this rapid procalcitonin testing among adults
admitted to the hospital with lower respiratory tract infection demonstrated
a large reduction in antibiotic use, and equivalent outcomes [122].
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Should antibiotics ever be used?
Antibiotic prescription rates for acute bronchitis range from 50% to 80%
in studies from multiple settings and countries [123–125]. Studies have failed
to show any meaningful benefit from antibiotics in the treatment of acute
bronchitis, however. Systematic reviews and meta-analyses of nine
randomized placebo-controlled trials conducted between 1970 and 2000
conclude that routine antibiotic treatment of acute bronchitis has no
consistent effect on either the duration or severity of illness. In one meta-
analysis, there was no significant impact on the duration of cough [126], but
two other meta-analyses reported a small but statistically significant
decrease in cough duration (one third days fewer of cough after 7 days)
associated with treatment with antibiotics [127,128]. In all three meta-
analyses, there was no significant impact on overall illness duration, activity
limitation, or work loss. A recent randomized, double-blind, controlled
study comparing azithromycin with vitamin C has addressed concerns that
the earlier trials were performed with older antibiotics, some of which had
no activity against the atypical agents implicated in acute bronchitis [129].
This study found no advantage to antibiotic treatment on illness outcomes
or return-to-work status.
As discussed earlier, antibiotic prescription is appropriate when the
physician suspects pertussis infection. Antibiotics should be reserved for
adults exposed to known pertussis infection, or to patients who have acute
bronchitis in the setting of a documented pertussis epidemic. Although
antibiotics do not decrease the duration of illness in this setting, they can
decrease bacterial shedding and spread. Antibiotics also may be considered
in the setting of a known mycoplasma or C pneumoniae outbreak, although
data are lacking on their effectiveness in this setting.
The harm of overusing antibiotics
The societal cost of inappropriate antibiotic use is the rapid emergence of
antibiotic resistance among bacterial pathogens [130–132]. Resistance is
rising among common community-acquired pathogens, including S pneumo-
niae (DRSP) [133–135]. This pathogen is a leading cause of ear and sinus
infections, pneumonia, sepsis, and meningitis in the United States. At the
community level, the mean increase in DRSP prevalence is directly
proportional to the amount of antibiotics consumed [136]. On an individual
level, a person’s risk for carriage, transmission, and invasive infection with
antibiotic-resistant bacteria is associated strongly with prior antibiotic use
[137–140].
Finally, the sheer magnitude of antibiotic prescriptions dispensed each
year for ARIs requires that excess health care costs also be considered. In
1998, 41 million antibiotic prescriptions were written for ARIs, 55% of
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was estimated at $726 million. Similar high rates of inappropriate antibiotic
use are seen in Europe [142]. In addition, the result of antibiotic resistance
on antibiotic selection and clinical outcomes further increases health care
costs [143].
If they don’t work, why are antibiotics so frequently prescribed for acute
bronchitis?
Physician education likely reflects a small component of inappropriate
antibiotic use. Evidence suggests that physicians and patients are more likely
to believe that antibiotics are appropriate if purulent secretions are present
[144,145], despite significant evidence to the contrary. Physician specialty
and level of training also are associated with antibiotic prescriptions for
ARIs. Family medicine physicians are more likely to prescribe antibiotics to
children with ARIs than pediatricians [146]. Also, providers that are further
from medical school graduation and practicing in rural areas are more likely
to prescribe antibiotics [147].
Antibiotic prescribing behavior is associated poorly with clinicians’
subjective norms and intentions, which suggests that external forces such as
patient-specific beliefs and health plan factors play a greater role [148] than
physician knowledge. Patients frequently expect to receive antibiotics for
uncomplicated acute bronchitis [149,150] and patients or parents who expect
antibiotics are more likely to receive them [150,151]. Communication
elements associated with antibiotic prescriptions for ARIs include patient
appeals to specific life circumstances (eg, a pressing social engagement),
identification of a previous positive experience with antibiotic use [81], or
being labeled as having ‘‘acute bronchitis’’ rather than a ‘‘chest cold’’ [149].
Not surprisingly, clinicians with greater patient workloads prescribe
antibiotics for ARIs more frequently, likely reflecting the perceived time it
would take to discuss the inappropriateness of antibiotic use in ARIs [152].
Other health plan factors that may contribute to prescribing behavior
include restricting formularies and practice characteristics such as payment
structure. A recent survey of physicians’ attitudes regarding the role of
societal risks in making antibiotic treatment decisions for individual patients
found that societal concerns about promoting antibiotic resistance ranked
below patient-centered factors such as ease of use and cost to the patient
[153].
Despite physician concerns about patient expectations, most studies find
that satisfaction with care for ARIs is tied more closely to how much time
the physician spent explaining the illness, rather than receipt of antibiotics
[150,151,154]. Communication elements associated with high patient
satisfaction include positive responses to the following statements: ‘‘the
doctor spent enough time with me’’; ‘‘the doctor explained the illness to
me’’; and ‘‘the doctor treated me with respect’’ [147]. An intervention
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prescription rates for acute bronchitis in adults [155], but did not decrease
patient satisfaction [147]. Furthermore, antibiotic prescribing does not seem
to reduce additional care seeking in adult patients [156].
Nonantibiotic treatment of acute bronchitis
Anti-influenzal therapy
Influenza is the most common cause of acute bronchitis, and influenza
vaccination is the most effective strategy for preventing influenzal illness.
Treatment for high-risk exposed individuals and those who present within
48 hours of symptom onset is also possible. Amantadine, rimantidine,
zanamivir, and oseltamivir decrease illness duration by approximately 1 day
and lead to a 0.5-day quicker return to normal activities [157]. The primary
difference between the agents is that the neuraminidase inhibitors are
effective against influenza A and B, whereas amantadine and rimantidine are
effective only against influenza A. The relative proportion of cases caused by
each type of influenza virus varies from year to year, and is determined best
through consultation with local public health agencies. Adverse events are
modestly more common with rimantidine (32% of patients, most commonly
central nervous system) than with the neuraminidase inhibitors (24% of
patients, mostly gastrointestinal) [157]. Because each of these therapies is
only effective if initiated within the first 48 hours, and preferably 30 hours,
of symptom onset, rapid diagnosis is key. During documented influenza
outbreaks, the positive predictive value of clinical diagnosis based on
clinician judgment is good (correct approximately 70% of the time) [158],
and compares favorably with rapid diagnostic tests for influenza (sensitiv-
ities of 63%–81%) [158–160]. Diagnosis of influenza in a nonoutbreak
period is more difficult and diagnostic testing should be considered.
Antiviral treatment for other viral illness either have been studied
inadequately, carry inappropriately high side-effect profiles, or are in-
effective in otherwise healthy individuals [161]. Ribavirin is indicated in
bone marrow transplant patients who have RSV, and in this population
reduces morbidity and mortality [162].
Bronchodilator therapy
Three randomized, controlled trials have demonstrated a consistent
benefit to bronchodilator treatment [163–165]. Approximately 50% fewer
patients report the presence of cough after 7 days of treatment. This benefit
seems to be greatest in the subset of patients who had bronchial
hyperresponsiveness. A large trail of patients who had URI-associated
cough, but not clearly acute bronchitis, reported no benefit of bronchodi-
lator treatment [166]. A meta-analysis of these studies showed no significant
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Littenberg study, which enrolled patients who had acute, nonspecific cough.
Whether anticholinergic bronchodilator therapy is effective in patients
who have uncomplicated acute bronchitis is not known. Similarly, no
studies have examined the effect of inhaled corticosteroid therapy, although
the delay in onset of action for this type of therapy (1–2 weeks) may
preclude finding a major benefit.
Antitussive therapy
The effectiveness of antitussive therapy seems to depend on the cause of
cough illness. Acute or early cough caused by colds and other upper
respiratory tract infections does not seem to respond to dextromethorphan
or codeine. Cough of greater than 3 weeks’ duration, cough associated with
underlying lung disease, and experimentally induced cough seem to respond
to these agents. Given that the cough of acute bronchitis often lasts for 2 to
3 weeks, these agents likely have a modest impact on cough severity and
duration.
Immunomodulating therapies
Most trials of immunomodulatory (alternative) therapies have been
conducted on patients who have early symptoms of colds and nonspecific
ARIs. As a result, these data are difficult to extrapolate to patients who have
acute bronchitis, who generally present later and with more severe illness.
Vitamin C at doses exceeding 1 g/d seems to offer small but significant
reduction in illness duration of about 0.5 day per cold episode [168]. Well-
performed clinical trials comprising mostly small studies of zinc gluconate
and zinc acetate lozenges have had mixed results [169] and their benefit is
unclear. Echinacea seems to be of benefit in some preparations [170], but
there is significant heterogeneity of study design, as well as preparations
tested. Also, quality control of echinacea preparations sold to the
community is poor, with one study demonstrating that 10% of single-herb
echinacea preparations in one metropolitan area had no active ingredient,
and less than half met the quality standards described on the label [171].
A recent randomized, double-blind, placebo-controlled trial has shown the
benefit of an extract of Pelargonium sidoides roots in acute bronchitis [172].
This plant extract is used commonly in Europe andMexico. Its mechanism of
action is poorly understood, but is believed to be immunomodulatory in
nature, having been used first in the early 1900s as a treatment for
tuberculosis. In the recent study, adult patients who had acute bronchitis of
greater than 48 hours’ duration and a bronchial severity score (BSS) of at least
5 points were enrolled. Patients were excluded if they were to receive or
recently had received antibiotics or had other serious illnesses. Patients were
randomized to receive active ingredient or color-, smell-, viscosity-, and taste-
matched placebo. Among patients receiving pelargonium, decrease in BSS on
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Duration of illness (P\ .001) and inability to work (16% versus 43%, P\
.0001) were significantly less in the pelargonium group compared with
placebo. Further studies are necessary to confirm these interesting results. In
the United States, Pelargonium sidioides is marketed under the trade name
Umcka (Nature’s Way, Springville, Utah).
Approach to the patient with acute bronchitis
The approach to the otherwise healthy patient with acute cough illness
first should be to assess his or her likelihood of pneumonia. In the
nonelderly patient without abnormal vital signs or consolidative lung
findings, the likelihood of pneumonia is less than 1% in the ambulatory care
setting [99,101]. When these abnormalities are present, a chest radiograph
should be considered, depending on overall clinical impression and
likelihood of influenza. For patients who present with prolonged cough
(longer than 1 week), pertussis should be considered, along with bronchial
hyperresponsiveness.
Once a diagnosis of acute bronchitis has been made, providers should
address symptomatic treatment and patient expectations for the visit.
Physicians should validate the severity of the patient’s illness (because it has
affected the patient’s activities enough to seek care and acute bronchitis
significantly decreases quality of life) [173]. Treatment discussions should
focus on alleviating symptoms and providing realistic expectations for the
duration of symptoms. Patients should be informed that they should expect
their cough to last 10 to 14 days after the office visit. Providers should also
inform patients of which symptoms should prompt a return to the clinic or
office.
For patients who request antibiotics for clear viral infections, providers
should discuss the lack of benefit and the risks of inappropriate antibiotic
use. These risks should be personalized as much as possible, informing them
that previous antibiotic use increases their personal risk of carriage and
infection with antibiotic-resistant infections. In addition, antibiotics cause
frequent side effects, especially of the gastrointestinal tract.
Symptomatic treatment will depend on severity of illness and time at
presentation. Alternative and over-the-counter preparations may be most
effective in the early stages of illness. For those with prolonged or severe
cough or clear bronchial hyperresponsiveness, bronchodilator treatment
and antitussives should be considered. Further studies are necessary on the
plant extract Pelargonium sidoides to assess further its benefit in this setting.
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